STIFEL 2026 HEALTHCARE CONFERENCE - EUPRAXIA PHARMACEUTICALS INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures disclosed in the transcript; company remains in clinical development stage without commercial sales.
• Funding structure implied to rely on capital raised to support clinical trials, with no mention of debt or deferred revenue.
• No industry-specific profitability metrics provided as the company is pre-revenue.

Guidance and Future Outlook:

• Timeline: Aiming to initiate Phase III trials for EOE in mid-2027.
• Clinical Readout: Anticipated release of interim Phase IIb data covering 6-month primary endpoints and 52-week durability data.
• Pipeline Expansion: Planning to evaluate Benign Esophageal Strictures (BES) around the same timeline, potentially via an adaptive Phase II/III design; Crohn's disease and Fibrotic Enterostomal conditions targeted for later phases.
• Commercial Goal: To leverage existing annual endoscopy guidelines (60% compliance) to drive therapy adoption once approved.

Business Segments and Product Lines:

• Core Technology: "Diffusphere," a delivery platform encapsulating APIs in ~100-micron balloons for direct tissue injection, providing zero-order kinetics with a duration of 52 weeks.
• Lead Candidate: Fluticasone (inhalational steroid repurposed) for Eosinophilic Esophagitis (EOE).
• Secondary Indications: Benign Esophageal Strictures (BES) and inflammatory bowel diseases (Crohn's, Ulcerative Colitis).
• Product Differentiation: Designed to align with standard-of-care annual endoscopies, transforming a diagnostic procedure into a therapeutic opportunity.

Market and Competitive Landscape:

• Market Size: EOE prevalence estimated at 500,000–600,000 patients in the U.S., up from 150,000 in 2022, driven primarily by improved diagnostic recognition.
• Competitive Set: Current treatments include daily oral dissolving tablets (budesonide) with poor compliance, weekly/bi-weekly biologics, and existing steroid injections (triamcinolone) which are off-label and short-acting.
• Physician Economics: Positioned as a "buy-and-bill" medical benefit (not pharmacy benefit), allowing gastroenterologists to bill a therapeutic CPT modifier (Modifier 59) for the 5–10 minute injection, potentially increasing practice revenue similar to the Intuvio model.
• Adoption Barriers: Current low endoscopy compliance (40% of eligible patients miss annual scopes) due to lack of therapeutic incentive; product aims to solve this by tying treatment to the procedure.

Risks and Challenges:

• Statistical Power: Interim trial not powered for statistical significance; success relies on demonstrating strong separation from placebo to justify full trial enrollment.
• Placebo Variability: High variability in symptom endpoints (DSQ/SDI) requires robust histological data (EOHSS) to confirm efficacy.
• Safety Profile: Need to demonstrate candidiasis rates significantly lower than the 5–25% seen with oral steroids (current data shows <2%, zero in trials).
• Regulatory Hurdles: Moving from open-label/open-data to rigorous Phase III registration; potential risks regarding statistical significance in smaller sample sizes (20-40 patients per arm for interim).

Management Commentary and Tone:

• Tone: Highly confident, emphasizing the transformative potential of the "one-year" dosing interval and the alignment with physician workflow.
• Key Narrative: Management argues that 6-month dosing is good, but 12-month dosing is "transformational" because it utilizes an existing, compliant medical procedure (endoscopy) rather than adding patient burden.
• Physician Sentiment: Strong support from gastroenterologists who view the procedure as low-risk (standard submucosal injection) and economically beneficial.
• Patient Compliance: Highlights that oral therapy compliance is low due to dietary restrictions post-dosing and high rates of candidiasis, whereas the injection requires no patient action post-procedure.

Analyst Questions and Answers:

• Q: Market Growth Drivers? A: Driven by increased diagnostic awareness rather than just environmental factors; historical undiagnosed patients are now being identified.
• Q: Why 1-year duration vs. 6-month? A: Aligns with standard-of-care annual endoscopy guidelines; eliminates the need for an additional procedure and induces compliance.
• Q: Confidence in Open-Label Data? A: High confidence that histological endpoints (EOHSS) will translate to placebo-controlled trials as placebo does not affect fibrosis/inflammation scores.
• Q: Safety and Training? A: Procedure is low risk; gastroenterologists perform similar submucosal injections daily for other indications; 3,000+ injections in trials with zero complications.
• Q: Statistical Significance Strategy? A: Trial protocol included "wiggle room" and pre-registered statistical analysis plans (SAP) to assess futility early; not powered for interim significance but designed to show separation.
• Q: Practice Economics? A: Drug is on the medical benefit; physicians bill a therapeutic facility fee, creating a revenue stream for endoscopy suites similar to the Intuvio launch model.

Other Key Points:

• Recruitment Speed: The trial recruited at twice the rate of previous EOE trials, attributed to physician enthusiasm for the therapeutic aspect and patient desire for a non-daily treatment.
• Endpoints: Interim data release will cover DSQ, SDI, EOHSS, EREFs, and safety, despite not being powered for statistical significance on these specific interim markers.
• Regulatory Path: Aiming for registrational data from the full Phase IIb/III transition, leveraging the over-enrolled trial status to maximize data yield.
• Historical Context: CEO emphasizes the shift in patient identity from "reflux sufferers" to recognized EOE patients over the last decade.